US Trials Show Novavax Covid Vaccine is More Than 90 Percent Effective
Novavax on Monday reported late-stage data from its U.S.-based clinical trial showing the vaccine is more than 90 percent effective against coronavirus across a variety of variants of the virus.
Gathogo Wanjiru 
The study conducted in nearly 30,000 volunteers in the US and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.
Novavax's protein-based coronavirus vaccine candidate was more than 93% effective against the predominant variants of COVID-19 that have been of concern among scientists and public health officials, Novavax said.
According to Novavax's head of research and development, Dr. Gregory Glenn, Novavax also worked against covid variants detected first in Brazil, South Africa, and India among its trial participants.
Novavax said the vaccine was generally well-tolerated among the participants and the only side effects experienced included headache, fatigue, and muscle pain and were generally mild. Only a small number of participants experienced side effects described as severe.
SII had said in March that U.S. restrictions on exports of supplies used for vaccines were limiting its ability to scale up production.
